Gail Farfel
Directeur/Membre du Conseil chez DURECT CORPORATION
Fortune : 118 764 $ au 31/05/2024
Profil
Gail M.
Farfel is currently a Director at DURECT Corp., PrintedArt, FAAH Pharma, Inc., Avrobio, Inc., and the American Society For Experimental Neurotherapeutics.
She previously served as the President, Chief Executive Officer & Director at ProMIS Neurosciences, Inc. from 2022 to 2023.
She also held positions as a Senior Associate Director at Pfizer Inc., Director at Zogenix International Ltd., Chief Clinical & Regulatory Officer at Marinus Pharmaceuticals, Inc. from 2012 to 2015, VP-Therapeutic Area & Head-Neuroscience at Novartis Pharmaceuticals Corp.
from 2006 to 2008, and Global Team Lead at Pfizer Pharmaceuticals, Inc. from 1994 to 2006.
Additionally, she was the President of G Meredith Consulting LLC in 2012 and the Chief Development Officer & Executive VP at Zogenix, Inc. from 2015 to 2022.
Dr. Farfel holds an undergraduate degree from the University of Virginia and a doctorate from The University of Chicago.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 23/08/2023 | 55 192 ( 0,29% ) | 101 664 $ | 31/05/2024 | |
DURECT CORPORATION
0,03% | 26/03/2024 | 10 000 ( 0,03% ) | 17 100 $ | 31/05/2024 |
AVROBIO INC
-.--% | 07/03/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Postes actifs de Gail Farfel
| Sociétés | Poste | Début |
|---|---|---|
| DURECT CORPORATION | Directeur/Membre du Conseil | 25/04/2019 |
| AVROBIO, INC. | Directeur/Membre du Conseil | 21/10/2020 |
PrintedArt
 PrintedArt Other Consumer ServicesConsumer Services PrintedArt provides photography and printing services. | Directeur/Membre du Conseil | - |
| American Society For Experimental Neurotherapeutics | Directeur/Membre du Conseil | - |
FAAH Pharma, Inc.
 FAAH Pharma, Inc. BiotechnologyHealth Technology FAAH Pharma, Inc. operates as a project-focused company developing a clinical asset initially for postherpetic neuralgia. The company was founded on June 26, 2014 and is headquartered in Montreal, Canada. | Directeur/Membre du Conseil | 07/08/2014 |
Anciens postes connus de Gail Farfel
| Sociétés | Poste | Fin |
|---|---|---|
| PROMIS NEUROSCIENCES, INC. | Directeur Général | 30/12/2023 |
| ZOGENIX, INC. | Corporate Officer/Principal | 01/09/2022 |
| MARINUS PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/06/2015 |
| G Meredith Consulting LLC | President | 01/12/2012 |
| ░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Gail Farfel
| University of Virginia | Undergraduate Degree |
| The University of Chicago | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| PFIZER, INC. | Health Technology |
| DURECT CORPORATION | Health Technology |
| MARINUS PHARMACEUTICALS, INC. | Health Technology |
| PROMIS NEUROSCIENCES, INC. | Health Technology |
| AVROBIO, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Zogenix, Inc.
 Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. | Health Technology |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Pfizer Pharmaceuticals, Inc.
 Pfizer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Pfizer Inc., Pfizer Pharmaceuticals, Inc. is an American company that manufactures pharmaceutical products. | Health Technology |
Zogenix International Ltd.
 Zogenix International Ltd. Pharmaceuticals: MajorHealth Technology Zogenix International Ltd. manufactures and markets pharmaceutical products. It develops Brabafen an oral treatment for use in children with Dravet Syndrome or severe myoclonic epilepsy of infancy. The company was founded in 2012 and is headquartered in Maidenhead, the United Kingdom. | Health Technology |
PrintedArt
PrintedArt Other Consumer ServicesConsumer Services PrintedArt provides photography and printing services. | Consumer Services |
FAAH Pharma, Inc.
FAAH Pharma, Inc. BiotechnologyHealth Technology FAAH Pharma, Inc. operates as a project-focused company developing a clinical asset initially for postherpetic neuralgia. The company was founded on June 26, 2014 and is headquartered in Montreal, Canada. | Health Technology |
| G Meredith Consulting LLC | |
| American Society For Experimental Neurotherapeutics |
